A randomized controlled trial found that patients hospitalized for an acute exacerbation of chronic obstructive poulmonary disease (COPD) experienced reduced rates of treatment failure when adding ...

An extended course of low-dose azithromycin (multiple brands) may significantly reduce treatment failure in patients hospitalized for acute exacerbation of chronic obstructive pulmonary disease (COPD) ...

The guideline from the Global Initiative for Chronic Obstructive Lung Disease (GOLD) does not recommend antibiotics for prevention of COPD exacerbations. Citing decades-old data on the lack of ...

Please provide your email address to receive an email when new articles are posted on . Azithromycin added to inhaled triple therapy in those with COPD and a recent exacerbation history was ...

Please provide your email address to receive an email when new articles are posted on . Patients receiving roflumilast vs. azithromycin had a reduced risk for COPD exacerbations at 1 year but an ...

Adding a common antibiotic to the usual daily treatment regimen for chronic obstructive pulmonary disease (COPD) can reduce the occurrence of acute exacerbations and improve quality of life, reports ...

May 3, 2019--The antibiotic azithromycin may reduce treatment failure in patients hospitalized for an acute exacerbation of chronic obstructive pulmonary disease (COPD), according to a randomized, ...

Idiopathic pulmonary fibrosis (IPF) is a progressive lung disorder of unknown etiology for which there is no effective therapy. Its course tends to be associated with acute exacerbations, each of ...

According to a meta-analysis, long-term macrolide therapy at low doses could reduce acute exacerbations in patients with chronic obstructive pulmonary disease. Long-term macrolide therapy at low doses ...

A research team from the LKS Faculty of Medicine at the University of Hong Kong (HKUMed) has highlighted recent advances in ...

Risk of pulmonary exacerbation down for children with cystic fibrosis, early Pseudomonas aeruginosa Nicole Mayer-Hamblett, PhD, from the University of Washington in Seattle, and colleagues conducted a ...